Enhancing ARIC Infastructure to Yield a New Cancer Epidemiology Cohort

增强 ARIC 基础设施以产生新的癌症流行病学队列

基本信息

批准号：
9188212
负责人：
ELIZABETH A. PLATZ
金额：
$ 21.88万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-05-15 至 2018-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9188212
关键词：
Address African American Atherosclerosis Biological Markers Blood Blood specimen Clinical Communities Consent DNA Sequence Data Diabetes Mellitus Diagnosis Epidemiologic Studies Food Frequencies Genetic study Handedness Health Histology Hospitals Instruction Interview Life Style Link Location Malignant Neoplasms Medical Medical Records Molecular Genetics Natural History Organ Participant Pathology Pharmaceutical Preparations Protocols documentation Questionnaires Records Recruitment Activity Recurrence Research Research Infrastructure Resources Retreatment Risk Schedule Site Specimen Staging Telephone Time Tissues Update Urine Variant Washington Woman adjudicate aged anticancer research cancer diagnosis cancer epidemiology cancer recurrence cohort cost fasting glucose follow-up genome wide association study neoplasm registry novel operation receptor response risk variant temporal measurement working group

项目摘要

We propose to enhance the infrastructure of ARIC, the Atherosclerosis Risk in Communities, cohort to yield a new Cancer Epidemiology Cohort that brings novel features to cancer epidemiology research. In 1987, 15,792 participants aged 45-64 years were recruited from Forsyth Co., NC; Jackson, MS; IVIinneapolis, MN; and Washington Co., MD. 55% are women and 27% are African-American. Participants underwent 4 clinical exams; a 5th is scheduled for 2011. Blood and urine specimens have been banked, medications recorded, and a food frequency questionnaire completed. Participants were interviewed by phone annually and now semi-annually to obtain updated health information. The response at year 21 is 91%. Because ARIC has never been viewed as a Cancer Epidemiology Cohort and infrastructure and cost constraints, only cancer diagnosis has been systematically recorded. By 2006, 3,145 participants were diagnosed with an incident first primary and 376 with a 2nd / 3rd primary. Information, such as stage, grade, histology, location in organ, laterality, receptor status, treatment, recurrence, and re-treatment, needed to address contemporary questions is not currently available. Tissue needed for molecular/genetic studies has not been collected. Thus, we propose: 1) Starting 2012, to prospectively identify cases from semi-annual phone interviews and collect medical/pathology records pertaining to cancer diagnosis, treatment, recurrence, and retreatment and tissue blocks. 2) To retrospectively collect information characterizing cancer diagnoses and recurrences before 2012 from cancer registries in the 4 ARIC states (consent already obtained) and medical records, and collect tissue blocks. By 2016, we expect 4,900 fully annotated incident cases. We established a Cancer Working Group to develop protocols for adjudicating cancer endpoints and prioritize research using the resource. With enhanced infrastructure, we expect that research questions such as these are addressable uniquely in ARIC: 1) What is the association between timing ofthe natural history of diabetes using 4 fasting glucose and 2 HbAlc measurements and timing of cancer diagnosis? 2) Using GWAS and sequencing data, is there a set of risk variants shared by major cancers or are variants specific to each site? RELEVANCE (See instructions): Given the wealth of repeated anthropometric, lifestyle, medical data, blood samples and biomarkers; GWAS on all participants; planned DNA sequencing; approved CMS linkage; 21-year follow-up; African-American representation; established hospital links; and existing operations protocols, with enhanced infrastructure, ARIC will be a mature Cancer Epidemiology Cohort that brings novel features to cancer research.

我们建议加强 ARIC 的基础设施，即社区动脉粥样硬化风险队列，以产生收益一个新的癌症流行病学队列为癌症流行病学研究带来了新的特征。 1987年，从北卡罗来纳州 Forsyth Co. 招募了 15,792 名年龄在 45-64 岁之间的参与者；杰克逊，MS； IV 明尼苏达州因尼阿波利斯；和华盛顿公司，MD。 55% 是女性，27% 是非裔美国人。参与者接受了4次临床考试； a 第 5 次定于 2011 年进行。血液和尿液样本已存入库，药物已记录，并完成食物频率调查问卷。参与者每年都会接受电话采访，现在每半年获取更新的健康信息。第 21 年的响应率为 91%。因为ARIC有从未被视为癌症流行病学队列以及基础设施和成本限制，只有癌症诊断已被系统记录。到 2006 年，已有 3,145 名参与者被诊断出发生了事故第一小学和 376 与第二/第三小学。信息，例如阶段、等级、组织学、器官中的位置，解决当代问题所需的偏侧性、受体状态、治疗、复发和再治疗目前无法提出问题。尚未收集分子/遗传学研究所需的组织。因此，我们建议： 1）从 2012 年开始，通过半年一次的电话访谈前瞻性地识别案例，收集与癌症诊断、治疗、复发和再治疗有关的医疗/病理记录，以及组织块。 2) 回顾性收集表征癌症诊断和复发的信息 2012 年之前来自 4 个 ARIC 州的癌症登记处（已获得同意）和医疗记录，以及收集组织块。到 2016 年，我们预计将有 4,900 个带有完整注释的事件案例。我们建立了癌症工作组制定用于裁定癌症终点的协议并优先考虑使用资源。随着基础设施的增强，我们预计诸如此类的研究问题是可以解决的 ARIC 中的独特之处：1) 使用 4 次禁食来确定糖尿病自然病程的时间之间有何关联？葡萄糖和 2 HbAlc 测量以及癌症诊断的时机？ 2）利用GWAS和测序数据，主要癌症是否存在一组共有的风险变异，或者每个部位都有特定的变异？相关性（参见说明）：鉴于大量的重复人体测量、生活方式、医疗数据、血液样本和生物标志物；全基因组关联分析对所有参与者；计划进行 DNA 测序；批准的 CMS 链接； 21年随访；非裔美国人表示;建立医院联系；和现有的操作协议，以及增强的基础设施， ARIC 将成为一个成熟的癌症流行病学队列，为癌症研究带来新的功能。